Related Experiment Video
Updated: Feb 27, 2026

The Tail Suspension Test
Published on: January 28, 2012
Recalibrating the risks and benefits of lithium therapy
Michael Berk1, Stephanie Cowdery2, Lana Williams2
1Michael Berk, MBBCh, MMed(Psych) Cum Laude, FF(Psych)SA, PhD, FRANZCP, Faculty of Health, School of Medicine, Deakin University; Stephanie Cowdery, BHSci, DLang, Grad Dip Psych(Hons), Lana Williams, BPsych, Grad Dip App Psych, MPsych (Clinical), PhD, IMPACT Strategic Research Centre, Faculty of Health, School of Medicine, Deakin University; Gin S. Malhi, MBChB, BSc(Hons), MD, FRCPsych, FRANZCP, CADE Clinic, North Shore Hospital, and Department of Psychiatry, University of Sydney, Australia mikebe@barwonhealth.org.au.
Abstract:
Recent data might subtly recalibrate the risk/benefit ratio of lithium, the prototypical mood stabiliser for bipolar disorder. There are hints that lithium might be associated with a reduction in dementia risk and as noted in this Journal, a surprising reduction in the risk of cancer.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Electroconvulsive Therapy
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Therapy
Antianxiety Medications
Dysrhythmias VII: Nursing Management of Dysrhythmias
Psychosis: Goals of Pharmacotherapy

